Skip to Main Content
Table 1—

Baseline demographic characteristics and efficacy variables of patients valid for safety analysis

CharacteristicsAcarbosePlaceboP
n 40 43  
Age (years) 58.37 ± 10.7 62.39 ± 8.02 0.127* 
Sex (%)   0.259 
 Female 35.0 23.3  
 Male 65.0 76.7  
Ethnicity (%)    
 White 80.0 97.7  
 Asian 5.0 0.0  
 Others 15.0 2.3  
Weight (kg) 89.77 ± 12.73 87.88 ± 11.7 0.632* 
BMI (kg/m230.75 ± 2.96 30.09 ± 2.85 0.086* 
Duration of diabetes (years) 5.32 ± 4.55 6.06 ± 5.32 0.757 
Daily metformin dosage (mg) 1,700 (500–4,000) 1,700 (500–3,000) 0.490 
HbAlc (%) 8.05 ± 0.89 7.82 ± 0.83 0.498* 
FBG (mmol/l) 9.97 ± 2.47 9.41 ± 1.99 0.719* 
CharacteristicsAcarbosePlaceboP
n 40 43  
Age (years) 58.37 ± 10.7 62.39 ± 8.02 0.127* 
Sex (%)   0.259 
 Female 35.0 23.3  
 Male 65.0 76.7  
Ethnicity (%)    
 White 80.0 97.7  
 Asian 5.0 0.0  
 Others 15.0 2.3  
Weight (kg) 89.77 ± 12.73 87.88 ± 11.7 0.632* 
BMI (kg/m230.75 ± 2.96 30.09 ± 2.85 0.086* 
Duration of diabetes (years) 5.32 ± 4.55 6.06 ± 5.32 0.757 
Daily metformin dosage (mg) 1,700 (500–4,000) 1,700 (500–3,000) 0.490 
HbAlc (%) 8.05 ± 0.89 7.82 ± 0.83 0.498* 
FBG (mmol/l) 9.97 ± 2.47 9.41 ± 1.99 0.719* 

Data are n, means ± SD, or median (min-max).

*

ANOVA with center and center by treatment interaction;

Cochran-Mantel-Haenszel test adjusting for center effect;

Wilcoxon’s rank-sum test.

Close Modal

or Create an Account

Close Modal
Close Modal